Skip to main content
. 2024 Nov 5;18:313–326. doi: 10.2147/BTT.S489363

Figure 6.

Figure 6

Duration of response of the 16 patients with previously treated advanced non-small cell lung cancer who achieved PR when received anlotinib plus PD-1 inhibitors.